Tier 2 — strong

A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults

Hao Huang
Frontiers in Aging 2022 3:851698

Bibliography

PubMed
PMID 35821806
PubMed Central
PMC9261366
DOI
10.3389/fragi.2022.851698
Competing interests
The author was employed by EffePharm (Shanghai) Co., Ltd., the company associated with the Uthever NMN product.

Study snapshot

DesignMulticentre, randomized, double-blind, parallel, placebo-controlled trial.
ModelHealthy middle-aged and older adults aged 40–65 years.
Sample70 people were screened and 66 were eligible/randomized. After unblinding, allocation was found to be 31 active and 35 placebo; the investigators then randomly selected 31 placebo participants for analysis, producing an analyzed sample of 62 (31 NMN, 31 placebo).
InterventionUthever β-NMN 300 mg/day versus starch placebo.
Duration60 days.
EndpointsSerum NAD+/NADH; Safety laboratory measures; SF-36 quality-of-life measures; Physiological measures

What the study showed, in plain terms

This multicentre study evaluated 300 mg/day Uthever NMN versus placebo for 60 days in middle-aged and older adults. Sixty-six eligible participants were randomized, but after unblinding the investigators found 31 active and 35 placebo participants and randomly selected only 31 placebo participants for the final analysis.

The paper reports higher NAD-related measures and favorable changes in some secondary health-status outcomes. Those results require caution because of the unusual post-unblinding subsampling, modest sample size, short duration, and the author's employment by the product company.

Key findings

  • Sixty-two participants completed the study, 31 per group.
  • The report described increases in NAD-related blood measures after NMN supplementation.
  • No major tolerability problem was identified over 60 days.
  • Some health-status outcomes favored NMN, but these were secondary and should not be treated as proof of broad clinical benefit.

What this study can and cannot tell us

Although 66 participants were randomized, the final analysis used 62: after unblinding revealed 31 active and 35 placebo participants, four placebo participants were removed by random selection to equalize group sizes. That post-unblinding analytic decision is nonstandard and can affect confidence in the between-group estimates. The study was also short, modest in size, and authored by an employee of the company associated with Uthever.

Citation network

Articles citing this research paper

4 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology